“Primary” and “secondary” muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes

por Pietzak, Eugene J., Al-Ahmadie, Hikmat, Walasek, Aleksandra, Bajorin, Dean F., Rosenberg, Jonathan E., Bochner, Bernard H., Solit, David B., Iyer, Gopa
Publicado 2019

Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes

por Solovyov, Alexander, Vabret, Nicolas, Arora, Kshitij S., Snyder, Alexandra, Funt, Samuel A., Bajorin, Dean F., Rosenberg, Jonathan E., Bhardwaj, Nina, Ting, David T., Greenbaum, Benjamin D.
Publicado 2018

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo

por Buckley, Michael T, Yoon, Joanne, Yee, Herman, Chiriboga, Luis, Liebes, Leonard, Ara, Gulshan, Qian, Xiaozhong, Bajorin, Dean F, Sun, Tung-Tien, Wu, Xue-Ru, Osman, Iman
Publicado 2007

A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor

por Leiserson, Mark D. M., Syrgkanis, Vasilis, Gilson, Amy, Dudik, Miroslav, Gillett, Sharon, Chayes, Jennifer, Borgs, Christian, Bajorin, Dean F., Rosenberg, Jonathan E., Funt, Samuel, Snyder, Alexandra, Mackey, Lester
Publicado 2018

Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic

por Sarfaty, Michal, Feldman, Darren R., Morris, Michael J., Motzer, Robert J., Rathkopf, Dana E., Regazzi, Ashley M., Iyer, Gopa, Voss, Martin H., Bajorin, Dean F., Rosenberg, Jonathan E.
Publicado 2021

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial

por Witjes, Johannes Alfred, Galsky, Matthew D., Gschwend, Jürgen E., Broughton, Edward, Braverman, Julia, Nasroulah, Federico, Maira-Arce, Mario, Ye, Xiaomei, Shi, Ling, Guo, Shien, Hamilton, Melissa, Bajorin, Dean F.
Publicado 2022

Single Arm Phase I/II Study of Everolimus and Intravesical Gemcitabine in Patients with Primary or Secondary Carcinoma In Situ of the Bladder who failed Bacillus Calmette Guerin (N...

por Dalbagni, Guido, Benfante, Nicole, Sjoberg, Daniel D., Bochner, Bernard H., Machele Donat, S., Herr, Harry W., Mc Coy, Asia S., Fahrner, Alicia J., Retinger, Caitlyn, Rosenberg, Jonathan E., Bajorin, Dean F.
Publicado 2017

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 Che...

por Tomita, Yoshihiko, Kobayashi, Ko, Kimura, Go, Oya, Mototsugu, Uemura, Hirotsugu, Nishiyama, Hiroyuki, Galsky, Matthew D, Nasroulah, Federico, Collette, Sandra, Broughton, Edward, Ünsal-Kaçmaz, Keziban, Kamisuki, Yukinori, Bajorin, Dean F
Publicado 2022

Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma

por Abida, Wassim, Milowsky, Matthew I., Ostrovnaya, Irina, Gerst, Scott R., Rosenberg, Jonathan E., Voss, Martin H., Apolo, Andrea B., Regazzi, Ashley M., McCoy, Asia S., Boyd, Mariel E., Bajorin, Dean F.
Publicado 2016

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)

por Rosenberg, Jonathan E., Park, Se Hoon, Kozlov, Vadim, Dao, Tu V., Castellano, Daniel, Li, Jian-Ri, Mukherjee, Som D., Howells, Kathryn, Dry, Hannah, Lanasa, Mark C., Stewart, Ross, Bajorin, Dean F.
Publicado 2023

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

por Grivas, Petros, Plimack, Elizabeth R., Balar, Arjun V., Castellano, Daniel, O’Donnell, Peter H., Bellmunt, Joaquim, Powles, Thomas, Hahn, Noah M., de Wit, Ronald, Bajorin, Dean F., Ellison, Misoo C., Frenkl, Tara L., Godwin, James L., Vuky, Jacqueline
Publicado 2020

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors

por Funt, Samuel A., McHugh, Deaglan J., Tsai, Stephanie, Knezevic, Andrea, O'Donnell, Devon, Patil, Sujata, Silber, Deborah, Bromberg, Maria, Carousso, Maryann, Reuter, Victor E., Carver, Brett S., Sheinfeld, Joel, Motzer, Robert J., Bajorin, Dean F., Bosl, George J., Feldman, Darren R.
Publicado 2021

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

por Sarfaty, Michal, Whiting, Karissa, Teo, Min Yuen, Lee, Chung‐Han, Peters, Vanessa, Durocher, Jennifer, Regazzi, Ashley M., McCoy, Asia S., Hettich, Grace, Jungbluth, Achim A., Al‐Ahmadie, Hikmat, Ostrovnaya, Irina, Chaim, Joshua, Bajorin, Dean F., Rosenberg, Jonathan E., Iyer, Gopa, Funt, Samuel A.
Publicado 2020

Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report

por Guercio, Brendan John, Iyer, Gopa, Kidwai, Wajih Zaheer, Lacouture, Mario E., Ghafoor, Soleen, Rossi, Anthony M., Assis, David N., Chen, Ying-Bei, Busam, Klaus J., Janjigian, Yelena Y., Jhaveri, Komal, Feldman, Darren R., Capozzi, Anne, Figueroa, Vanessa, Bajorin, Dean F., Rosenberg, Jonathan E., Hollmann, Travis J., Funt, Samuel A.
Publicado 2021

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

por Snyder, Alexandra, Nathanson, Tavi, Funt, Samuel A., Ahuja, Arun, Buros Novik, Jacqueline, Hellmann, Matthew D., Chang, Eliza, Aksoy, Bulent Arman, Al-Ahmadie, Hikmat, Yusko, Erik, Vignali, Marissa, Benzeno, Sharon, Boyd, Mariel, Moran, Meredith, Iyer, Gopa, Robins, Harlan S., Mardis, Elaine R., Merghoub, Taha, Hammerbacher, Jeff, Rosenberg, Jonathan E., Bajorin, Dean F.
Publicado 2017

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma

por Teo, Min Yuen, Al-Ahmadie, Hikmat, Seier, Kenneth, Tully, Christopher, Regazzi, Ashley M., Pietzak, Eugene, Solit, David B., Tickoo, Satish, Reuter, Victor, Cha, Eugene K., Herr, Harry, Donahue, Timothy, Donat, Sherri M., Dalbagni, Guido, Bochner, Bernard H., Funt, Samuel, Iyer, Gopakumar V., Bajorin, Dean F., Ostrovnaya, Irina, Rosenberg, Jonathan E.
Publicado 2021

Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

por Holm, Jeppe Sejerø, Funt, Samuel A., Borch, Annie, Munk, Kamilla Kjærgaard, Bjerregaard, Anne-Mette, Reading, James L., Maher, Colleen, Regazzi, Ashley, Wong, Phillip, Al-Ahmadie, Hikmat, Iyer, Gopa, Tamhane, Tripti, Bentzen, Amalie Kai, Herschend, Nana Overgaard, De Wolf, Susan, Snyder, Alexandra, Merghoub, Taha, Wolchok, Jedd D., Nielsen, Morten, Rosenberg, Jonathan E., Bajorin, Dean F., Hadrup, Sine Reker
Publicado 2022

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

por Clinton, Timothy N., Chen, Ziyu, Wise, Hannah, Lenis, Andrew T., Chavan, Shweta, Donoghue, Mark T.A., Almassi, Nima, Chu, Carissa E., Dason, Shawn, Rao, Pavitra, Rodrigues, James A., Vasani, Naresh B., Ridouani, Fourat, Rosenberg, Jonathan E., Bajorin, Dean F., Teo, Min Yuen, Bochner, Bernard H., Berger, Michael F., Ostrovnaya, Irina, Pietzak, Eugene J., Iyer, Gopa, Gao, Sizhi Paul, Hu, Wenhuo, Al-Ahmadie, Hikmat A., Solit, David B.
Publicado 2022

Fundamental immune–oncogenicity trade-offs define driver mutation fitness

por Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D.
Publicado 2022

Author Correction: Fundamental immune–oncogenicity trade-offs define driver mutation fitness

por Hoyos, David, Zappasodi, Roberta, Schulze, Isabell, Sethna, Zachary, de Andrade, Kelvin César, Bajorin, Dean F., Bandlamudi, Chaitanya, Callahan, Margaret K., Funt, Samuel A., Hadrup, Sine R., Holm, Jeppe S., Rosenberg, Jonathan E., Shah, Sohrab P., Vázquez-García, Ignacio, Weigelt, Britta, Wu, Michelle, Zamarin, Dmitriy, Campitelli, Laura F., Osborne, Edward J., Klinger, Mark, Robins, Harlan S., Khincha, Payal P., Savage, Sharon A., Balachandran, Vinod P., Wolchok, Jedd D., Hellmann, Matthew D., Merghoub, Taha, Levine, Arnold J., Łuksza, Marta, Greenbaum, Benjamin D.
Publicado 2022